Choudhuri, Avik
Trompouki, Eirini http://orcid.org/0000-0002-7242-8810
Abraham, Brian J. http://orcid.org/0000-0001-8085-3027
Colli, Leandro M.
Kock, Kian Hong
Mallard, William http://orcid.org/0000-0002-2271-945X
Yang, Min-Lee
Vinjamur, Divya S. http://orcid.org/0000-0002-9369-0412
Ghamari, Alireza
Sporrij, Audrey
Hoi, Karen
Hummel, Barbara
Boatman, Sonja
Chan, Victoria
Tseng, Sierra
Nandakumar, Satish K. http://orcid.org/0000-0002-7853-426X
Yang, Song
Lichtig, Asher
Superdock, Michael http://orcid.org/0000-0003-4165-4425
Grimes, Seraj N.
Bowman, Teresa V.
Zhou, Yi
Takahashi, Shinichiro
Joehanes, Roby
Cantor, Alan B.
Bauer, Daniel E. http://orcid.org/0000-0001-5076-7945
Ganesh, Santhi K.
Rinn, John
Albert, Paul S.
Bulyk, Martha L.
Chanock, Stephen J. http://orcid.org/0000-0002-2324-3393
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Zon, Leonard I. http://orcid.org/0000-0003-0860-926X
Article History
Received: 15 April 2019
Accepted: 14 October 2020
First Online: 23 November 2020
Competing interests
: L.I.Z. is a founder and stockholder of Fate Therapeutics, CAMP4 Therapeutics, Amagma Therapeutics, and Scholar Rock. He is a consultant for Celularity and Cellarity. R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. B.J.A. is a shareholder in Syros Pharmaceuticals. M.L.B. is a co-inventor on patents on PBM technology. The other authors declare no competing interests.